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Abstract
Background: The utilization of mechanical circulatory support (MCS) for percutaneous
coronary intervention (PCI) using percutaneous ventricular assist device (PVAD) or intra-
aortic balloon pump (IABP) has been increasing. We sought to evaluate the outcome of
coronary intervention using PVAD compared with IABP in noncardiogenic shock and
nonacute myocardial infarction patients.
Method: Using the National Inpatient Sampling (NIS) database from 2005 to 2014,
we identified patients who underwent PCI using ICD 9 codes. Patients with cardio-
genic shock, acute coronary syndrome, or acute myocardial infarction were excluded.
Patient was stratified based on the MCS used, either to PVAD or IABP. Univariate
and multivariate logistic regression were performed to study PCI outcome using
PVAD compared with IABP.
Results: Out of 21,848 patients who underwent PCI requiring MCS, 17,270 (79.0%)
patients received IABP and 4,578 (21%) patients received PVAD. PVAD patients were
older (69 vs. 67, p < .001), were less likely to be women (23.3% vs. 33.3%, p < .001), and
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had higher rates of hypertension, diabetes, hyperlipidemia prior PCI, prior coronary artery
bypass graft surgery, anemia, chronic lung disease, liver disease, renal failure, and periph-
eral vascular disease compared with IABP group (p ≤ .007). Using Multivariate logistic
regression, PVAD patients had lower in-hospital mortality (6.1% vs. 8.8%, adjusted odds
ratio [aOR] 0.62; 95% CI 0.51, 0.77, p < .001), vascular complications (4.3% vs. 7.5%,
aOR 0.78; 95% CI 0.62, 0.99, p = .046), cardiac complications (5.6% vs. 14.5%, aOR 0.29;
95% CI 0.24, 0.36, p < .001), and respiratory complications (3.8% vs. 9.8%, aOR 0.37;
95% CI 0.28, 0.48, p < .001) compared with patients who received IABP.
Conclusion: Despite higher comorbidities, nonemergent PCI procedures using PVAD
were associated with lower mortality compared with IABP.
K E YWORD S
coronary interventions, high-risk intervention, mechanical circulatory support
1 | INTRODUCTION
Percutaneous mechanical circulatory support (MCS) devices are often
used during percutaneous coronary intervention (PCI) to maintain sys-
temic perfusion. Patients with multiple comorbidities and complex
multi-vessel coronary artery disease are increasingly referred for
HRPCI.1 Complex high-risk indicated patients or what is referred to as
(CHIP), are defined by the presence of one of the following: unpro-
tected left main, last patent coronary conduit, a vessel supplying a
large myocardial territory with severely depressed ejection fraction
(EF), patient who need high risk coronary interventional technique to
achieve revascularization, or a vessel supplying a large territory in the
setting of cardiogenic shock.2 During PCI, a transient interruption of
blood flow to target vessels occurs, leading to a myocardial function
deterioration, which in turn, results in hemodynamic compromise that
can affect procedural outcome.3 Providing hemodynamic support for
this patient population using a number of available devices may
reduce such peri-procedural hemodynamic compromise.4–7 Indeed,
recent studies and contemporary registries showed increased utiliza-
tion of MCS for PCI with improved long-term outcomes.8,9 The cur-
rent guidelines also provide Class IIb for elective insertion of an
appropriate hemodynamic support device in carefully selected
patients.10 Despite the lack of clear evidence, the utilization of PVAD
has increased substantially. Given the limited information in compara-
tive studies, we sought to provide further insights into the trend of
MCS use for patients undergoing PCI using large hospitalization data-
base and to compare the utilization and outcomes in patients who had
PCIs performed with IABP versus PVAD.
F IGURE 1 Identification of
study population using national
inpatient sampling database.
IABP, intra-aortic balloon pump;
PCI, percutaneous coronary
intervention; PVAD,
percutaneous ventricular assist
device [Color figure can be
viewed at wileyonlinelibrary.com]
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TABLE 1 Baseline characteristics in patients undergoing
percutaneous coronary intervention requiring hemodynamic support
Variable
PVAD
group
IABP
group p value
Age (years) 69.28
± 11.73
67.40
± 11.68
<.001
Sex
Female (%) 23.3 33.3 <.001
Race (%) <.001
White 72.4 77.3
Black 7.8 10.2
Hispanic 7.6 8.0
Asian or Pacific islander 3.5 2.8
Native American 0.5 0.7
Other 5.4 3.8
Elective hospitalization (%) 45.8 38.7 <.001
Primary expected payer (%) <.001
Medicare 68.8 61.8
Medicaid 7.0 6.4
Private insurance 20.4 26.5
Self-pay 1.6 3.1
No charge 0.0 0.1
Other 2.3 2.1
Median household income (%) <.001
0–25 percentile 32.2 26.1
26–50 percentile 25.8 25.7
51–75 percentile 22.4 24.0
76–100 percentile 19.6 24.2
Bed size (%) .093
Small 8.1 7.1
Medium 20.6 20.8
Large 71.3 72.1
Location/teaching status (%) <.001
Rural 7.3 2.6
Urban nonteaching 34.3 26.1
Urban teaching 58.4 71.2
Hospital region (%) <.001
Northeast 20.8 19.0
Midwest 23.8 23.6
South 35.2 34.5
West 20.2 22.9
Number of vessels operated
on (%)
<.001
One vessel 40.9 66.7
Two vessels 36.4 24.7
Three vessels 17.6 6.6
Four or more vessels 5.0 2.0
Number of stents inserted
during PCI (%)
<.001
(Continues)
TABLE 1 (Continued)
Variable
PVAD
group
IABP
group p value
One stent 34.4 42.0
Two stents 31.4 31.9
Three stents 18.8 15.0
Four or more stents 15.5 11.2
Comorbidities
Hypertension (%) 73.3 67.8 <.001
Diabetes mellitus,
uncomplicated (%)
35.9 29.8 <.001
Diabetes mellitus,
complicated (%)
8.1 5.7 <.001
Dyslipidemia (%) 57.3 56.4 .259
Atrial fibrillation (%) 18.5 13.8 .097
CAD (%) 74.6 75.5 .233
Prior PCI (%) 15.6 14.0 .007
Prior CABG (%) 9.1 7.5 <.001
Prior stroke/TIA (%) 7.1 3.4 <.001
Carotid disease (%) 5.1 5.4 .378
Smoking (%) 10.1 12.5 <.001
Acquired immune
deficiency (%)
0.4 0.2 .002
Alcohol abuse (%) 1.7 2.1 .094
Deficiency anemia (%) 18.4 16.3 .001
Rheumatoid
arthritis/collagen vascular
disease (%)
2.4 2.1 .214
Chronic blood loss
anemia (%)
1.0 1.1 .669
Congestive heart failure (%) 1.9 2.5 .020
Chronic pulmonary
disease (%)
21.6 21.2 .476
Depression (%) 5.8 6.0 .600
Coagulopathy (%) 5.7 9.6 <.001
Drug abuse (%) 1.2 1.1 .626
Hypothyroidism (%) 9.5 9.9 .414
Liver disease (%) 2.3 1.2 <.001
Lymphoma (%) 0.6 0.8 .338
Fluid and electrolytes
disturbances (%)
17.0 19.1 .001
Metastatic cancer (%) 0.5 0.3 .074
Solid tumor without
metastasis (%)
0.8 1.7 <.001
Other neurological
disorders (%)
2.9 4.3 <.001
Obesity (%) 12.4 11.7 .255
Paralysis (%) 1.5 1.4 .509
Psychosis (%) 1.1 1.9 <.001
Renal failure (%) 28.0 17.7 <.001
(Continues)
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2 | METHODS
2.1 | Study population
The National Inpatient Sample (NIS) is a publicly available and iden-
tified database of hospital discharges in the United States, con-
taining data from approximately 8 million hospital stays that were
selected using a complex probability sampling design, and the
weighting scheme recommended by the Agency for Healthcare
Research and Quality which is intended to represent all discharges
from nonfederal hospitals.11 Each record includes one primary diag-
nosis and up to 14 secondary diagnoses from the years 2005 to
2008, 24 secondary diagnosis codes between 2009 and 2013, and
29 secondary diagnosis codes in 2014. We obtained NIS data from
2005 to 2014 and used the International Classification of Disease,
Ninth Edition, Clinical Modification (ICD-9-CM) codes to identify
all patients aged ≥18 who underwent PCI. PCI was identified using
the ICD-9-CM procedure codes 36.06, 36.07, 00.66, 00.40, 00.41,
00.42, 00.43, 00.44, 00.45, 00.46, 00.47, and 00.48. We excluded
patients with cardiogenic shock who were identified using ICD-
9-CM diagnosis code 785.51 as well as excluding acute myocardial
infection patients using clinical classification codes provided by the
Agency for Healthcare Research and Quality. Patients with PVAD
and IABP were identified using the ICD-9-CM procedure code
37.68 and 37.61, respectively (Figure 1).
2.2 | Patient and hospital characteristics
Data were retrieved retrospectively. Baseline patient-level charac-
teristics included demographics (age, sex, race, primary expected
payer, median household income for patient's zip code), urgency of
the procedure (elective vs. nonelective), all of the Elixhauser com-
orbidities and other relevant comorbidities (smoking, hyperlipid-
emia, coronary artery disease (CAD), Prior percutaneous coronary
intervention (PCI), prior coronary artery bypass grafting (CABG),
prior stroke/transient ischemic attack (TIA), atrial fibrillation,
carotid artery disease). Hospital-level characteristics were census
region, bed size, and teaching status. Using the Clinical Classifica-
tion Software codes provided by the Healthcare Cost and Utiliza-
tion Project and the Elixhauser Comorbidity Index comorbidities
were appointed via ICD-9 codes. A list of ICD-9-CM codes and
Clinical Classification Software codes used to identify com-
orbidities is included in Supporting Information Table S1.
2.3 | Outcome measures
The primary outcome of interest was in-hospital mortality. In-hospital
complications included bleeding requiring transfusion, major vascular
complications (injury to blood vessel, accidental puncture, injury to
retroperitoneum, other vascular complications, or any vascular complica-
tions requiring surgery), cardiac complications (Iatrogenic cardiac compli-
cations, hemopericardium, cardiac tamponade, pericardiocentesis),
respiratory complications (postoperative acute pneumothorax, postoper-
ative pulmonary edema, pulmonary collapse, prolonged mechanical venti-
lation >96 hours, tracheostomy), postprocedural stroke and acute kidney
injury (AKI). Length of stay (LOS) and discharge to an outside facility
were also included in the secondary outcomes. A list of ICD-9-CM diag-
nosis codes used to identify in-hospital outcomes is included in
Supporting Information Table S1.
2.4 | Statistical analysis
Continuous variables were expressed as weighted mean values ±
standard deviation (normal distribution) or median with inter-
quartile range (non-normal distribution), and categorical variables
were expressed as percentages. Independent t-tests were used
for the comparison of continuous variables measurements, while
chi-square test for categorical variables. Weighted values of
patient level observations were generated to produce a nationally
representative estimate of the entire US population of hospital-
ized patients. Univariate and multivariate logistic regression
analysis were used to compare in-hospital mortality and complica-
tions between both groups. The regression model was adjusted
for demographics (age, race and gender), patients' insurance,
socioeconomic status, calendar year, hospital characteristics, pro-
cedure urgency (elective vs. nonelective), number of vessels oper-
ated on, number of stents inserted, and all comorbidities listed in
Table 1. Adjusted odds ratios (aORs) and 95% confidence inter-
vals (CIs) were used to report the results of regression models.
Linear regression models were used to assess the LOS. Log trans-
formation of LOS was done to adjust for positively skewed data.
To further explore the validity of our findings, we performed
propensity score-matching analysis between PVAD and IABP
groups. All patients in both groups were matched for baseline
characteristics, hospital characteristics, patients' socioeconomic
status and insurance and procedure characteristics in 1:3 propen-
sity score matching analysis, using nearest neighbor method. For
the trend analysis, Cochrane–Armitage test was used to
TABLE 1 (Continued)
Variable
PVAD
group
IABP
group p value
Peripheral vascular
disease (%)
24.0 17.3 <.001
Pulmonary circulation
disorders (%)
0.3 0.5 .143
Peptic ulcer disease
excluding bleeding (%)
0.0 0.0 .207
Valvular disease (%) 0.6 1.0 .039
Weight loss 2.8 3.2 .102
Note: Values are expressed as mean ± SD for continuous variables or
percentages for categorical variables.
Abbreviations: CABG, coronary artery bypass grafting; CAD, coronary
artery disease; IABP, intra-aortic balloon pump; PCI, percutaneous
coronary intervention; PVAD, percutaneous ventricular assist device;
TIA, transient ischemic attack.
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determine the presence of a linear trend between PVAD and
IABP utilization over the studied calendar years. p value of less
than .05 was considered statistically significant. SPSS version
25 software (IBM Corp, Armonk, NY) was used for all statistical
analyses.
3 | RESULTS
3.1 | Baseline characteristics
A total of 21,848 patients underwent PCI from 2005 to 2014 using
MCS. Out of 21,848 patients, 17,270 (79.0%) received IABP and
4,578 (21%) received PVAD. Baseline characteristics for both
groups are summarized in Table 1. Compared with patients who
received IABP (mean age 67.4 ± 11.7 years), patients with PVAD
were older (mean age 69.3 ± 11.7 years), less likely to be women or
African American (p < .001 for all). The prevalence of complicated
and uncomplicated diabetes, hypertension, prior stroke/TIA, prior
PCI, prior CABG, liver disease, renal failure, valvular disease,
peripheral vascular disease, acquired immune deficiency, and defi-
ciency anemia was higher among patients who received PVAD.
Smoking, congestive heart failure, coagulopathy, fluid and electro-
lyte disturbances, solid tumors, other neurological disorders, and
psychosis were more prevalent in IABP patients (p ≤ .007 for all).
F IGURE 2 Utilization trend of hemodynamic
support in patients who underwent percutaneous
coronary interventions. IABP, intra-aortic balloon
pump; PVAD, percutaneous coronary intervention
[Color figure can be viewed at
wileyonlinelibrary.com]
TABLE 2 Multivariate logistic regression for the outcome of percutaneous coronary intervention in patients requiring PVAD compared
patients requiring IABP
Outcome PVAD IABP
UOR (95% CI) PVAD
(when compared
with IABP)
aOR (95% CI) PVAD
(when compared
with IABP)
Unadjusted
p value
Adjusted
p value
Overall (n) 4,578 17,270
In-hospital mortality (%) 6.1 8.8 0.675 (0.592–0.770) 0.629 (0.513–0.771) <.001 <.001
Length of stay (IQR) 4 days
(2–8 days)
5 days
(3–10 days)
<.001
Hemorrhage requiring
transfusion (%)
2.7 2.8 0.956 (0.781–1.169) 1.083 (0.817–1.435) .659 .581
Vascular complications (%) 4.3 7.5 0.558 (0.479–0.650) 0.787 (0.622–0.996) <.001 .046
Cardiac complications (%) 5.6 14.5 0.351 (0.308–0.401) 0.299 (0.247–0.362) <.001 <.001
Respiratory complications (%) 3.8 9.8 0.361 (0.308–0.424) 0.375 (0.288–0.488) <.001 <.001
Postprocedural stroke (%) 5.7 3.0 1.936 (1.662–2.255) 0.656 (0.391–1.099) <.001 .109
AKI (%) 15.1 14.1 1.086 (0.991–1.190) 0.914 (0.793–1.053) .077 .215
Discharge to facility (%) 10.7 14.9 0.686 (0.619–0.760) 1.003 (0.863–1.166) <.001 .972
Note: Unadjusted odds ratios are displayed given low event rate.
Abbreviations: AKI, acute kidney injury; aOR, adjusted odds ratio; IABP, intra-aortic balloon pump; IQR, interquartile range; PVAD, percutaneous
ventricular assist device; UOR, unadjusted odds ratio.
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PVAD patients had more patients undergoing interventions in
2 vessels (36.4% vs. 24.7%), 3 vessels (17.6% vs. 6.6%) and 4 or
more vessels compared with IABP patients (5.0% vs. 2.0%; p < .001
for all). Additionally, the PVAD group had more patients with
3 stents insertion during the procedure (18.8% vs. 15.0%) and 4 or
more stents (15.5% vs. 11.2%) compared with the IABP group
(p < .001 for all). Patients with PVAD were less likely to have pri-
vate insurance, and more likely have median household income in
the lowest quartile, compared with IABP patients (p < .001). Elec-
tive admissions were more frequent in patients who received PVAD
(p < .001).
Using the Cochrane–Armitage method, we found a statistically
significant linear uptrend in the utilization of PVAD from 19 (1.0%) to
1,040 (42.6%) cases between the years 2005 and 2014; whereas the
linear trend for the utilization of IABP was down trending from 1,930
(99.0%) to 1,400 (57.4%) cases between 2005 and 2014 (P-
Trend < 0.001, for all; Figure 2).
3.2 | In-hospital outcomes
In-hospital mortality was significantly lower in patients who
received PVAD compared with patients who received IABP (6.1%
vs. 8.8%, p < .001). After adjusting for patients' demographics, pro-
cedure urgency, comorbidities, insurance and socioeconomic status
using multivariate regression mode, PVAD patients remained at
lower risk of in-hospital mortality (adjusted OR: 0.62 [95% CI:
0.51–0.77]; Table 2). Risk-adjusted linear regression for LOS dem-
onstrated a statistically significant shorter LOS in the PVAD group
(median LOS = 4 days; Interquartile range [IQR] (2–8)) when
compared with those with IABP (median LOS = 5 days; [IQR]
(3–10); p < .001).
Patients with PVAD had lower incidence of vascular complica-
tions (4.3% vs. 7.5%, p = .046), cardiac complications (5.6%
vs. 14.5%, p < .001) and respiratory complications (3.8% vs. 9.8%,
p < .001), but higher incidence of postprocedural stroke (5.7%
vs. 3.0%, p < .001; Figure 3). After multivariate risk adjustment, the
risk of vascular complications (adjusted OR: 0.78 [95% CI:
0.62–0.99]), cardiac complications (adjusted OR: 0.29 [95% CI:
0.24–0.36]), and respiratory complications (adjusted OR: 0.37 [95%
CI: 0.28–0.48]) remained significantly lower in PVAD group;
whereas postprocedural stroke showed no statistically significant
difference between the PVAD group and IABP group (adjusted OR:
0.65 [95% CI: 0.39–1.09]). Furthermore, no statistically significant
difference was found between PVAD patients and IABP patients in
terms of bleeding requiring transfusion, discharge to an outside
facility and AKI (2.7% vs. 2.8%, p = .581), (10.7% vs. 14.9%,
p = .972), (15.1% vs. 14.1%, p = .215), respectively. The two groups
continue to have no statistically significant difference in terms of
bleeding requiring transfusion or AKI even with multivariate risk
adjustment (adjusted OR: 1.08 [95% CI: 0.81–1.43] and 0.91 [95%
CI: 0.79–1.05], respectively; Table 2).
3.3 | Propensity-score matching and in-hospital
outcomes
Baseline characteristics of the propensity matched IABP and PVAD
groups are shown in Table 3. Patients who received PVAD had
lower in-hospital mortality (3.5% vs. 6.4, OR: 0.53, 95% CI:
F IGURE 3 Incidence of death and adverse cardiovascular outcomes after percutaneous coronary interventions in PVAD patient versus IABP
patients. IABP, intra-aortic balloon pump; PVAD, percutaneous coronary intervention; AKI, acute kidney injury [Color figure can be viewed at
wileyonlinelibrary.com]
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TABLE 3 Propensity score matching baseline characteristics
between PVAD and IABP groups in patients undergoing percutaneous
coronary intervention requiring hemodynamic support
Variable
PVAD
group
IABP
group p value
Age (years) 69.30
± 11.89
68.63
± 11.39
.230
Sex
Female (%) 23.2 26.2 .146
Race (%) .251
White 72.2 75.7
Black 9.5 6.4
Hispanic 8.5 8.7
Asian or Pacific islander 3.5 3.4
Native American 0.5 0.6
Other 5.8 5.3
Elective hospitalization (%) 49.4 43.8 .022
Primary expected payer (%) .010
Medicare 70.3 65.3
Medicaid 6.8 6.3
Private insurance 19.5 25.1
Self-pay 1.3 2.2
No charge 0.0 0.2
Other 2.3 1.0
Median household income
(%)
.276
0–25 percentile 29.7 26.0
26–50 percentile 25.2 25.2
51–75 percentile 22.8 23.5
76–100 percentile 22.2 25.2
Bed size (%) .718
Small 9.2 8.3
Medium 21.7 20.9
Large 69.1 70.8
Location/teaching
status (%)
.026
Rural 2.7 4.1
Urban nonteaching 27.0 31.5
Urban teaching 70.3 64.3
Hospital region (%) .559
Northeast 21.4 22.3
Midwest 23.6 22.0
South 32.3 30.6
West 22.7 25.1
Number of vessels
operated on (%)
<.001
One vessel 41.6 52.4
Two vessels 37.6 34.4
Three vessels 15.9 10.2
(Continues)
TABLE 3 (Continued)
Variable
PVAD
group
IABP
group p value
Four or more vessels 4.8 3.1
Number of stents inserted
during PCI (%)
.156
One stent 34.4 39.4
Two stents 33.1 32.1
Three stents 18.5 16.3
Four or more stents 14.0 12.2
Comorbidities
Hypertension (%) 76.8 73.5 .111
Diabetes mellitus,
uncomplicated (%)
36.7 34.7 .392
Diabetes mellitus,
complicated (%)
7.4 6.4 .398
Dyslipidemia (%) 60.1 60.3 .951
Atrial fibrillation (%) 18.3 17.6 .712
CAD (%) 74.4 73.8 .783
Prior PCI (%) 16.6 16.8 .897
Prior CABG (%) 10.0 9.5 .750
Prior stroke (%) 6.8 4.8 .070
Carotid disease (%) 5.1 4.4 .498
Smoking (%) 11.9 11.2 .651
Acquired immune
deficiency (%)
0.3 0.2 .712
Alcohol abuse (%) 2.3 2.1 .884
Deficiency anemia (%) 19.1 18.1 .584
Rheumatoid
arthritis/collagen
vascular disease (%)
2.7 2.4 .639
Chronic blood loss
anemia (%)
0.5 0.4 .721
Congestive heart
failure (%)
1.8 2.4 .392
Chronic pulmonary
disease (%)
22.7 21.7 .632
Depression (%) 5.9 6.3 .772
Coagulopathy (%) 5.6 5.6 .979
Drug abuse (%) 1.0 1.2 .612
Hypothyroidism (%) 9.6 10.3 .668
Liver disease (%) 2.4 1.6 .225
Lymphoma (%) 0.5 0.6 .721
Fluid and electrolytes
disturbances (%)
16.6 17.0 .799
Metastatic cancer (%) 0.6 0.3 .283
Solid tumor without
metastasis (%)
1.0 1.1 .825
Other neurological
disorders (%)
2.7 3.6 .319
Obesity (%) 13.3 12.6 .638
(Continues)
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0.33–0.87, p = .012), vascular complications (3.4% vs. 6.0%, OR:
0.54, 95% CI: 0.33–0.89, p = .017), cardiac complications (3.4%
vs. 12.2%, OR: 0.25,95% CI: 0.15–0.40, p < .001), and respiratory
complications (2.6% vs. 6.1%, OR: 0.40, 95% CI: 0.23–0.69,
p = .001; Table 4). There were no differences in the rates of post-
procedural stroke between the PVAD and IABP group (5.0%
vs. 3.7%, p = .120). Standardized differences of covariates between
IABP and PVAD groups before and after matching are shown in
Supporting Information Figure S1.
4 | DISCUSSION
The main findings of this study are: (a) The utilization of PVAD for PCI
without cardiogenic shock has been increased over time while IABP use
has decreased. (b) Patients who received PVAD as MCS device for per-
cutaneous coronary intervention had lower in-hospital mortality com-
pared with those who received IABP. (c) The incidence of vascular
complications, cardiac complications and respiratory complications was
lower also in patients who received PVAD compared with IABP.
(d) Length of stay of patients in the PVAD group was shorter compared
with patients in the IABP group.
As the techniques utilized in PCI procedures evolve, the number
of high-risk patients referred for PCI has increased as well. Patients
who are referred to the catheterization laboratory for HRPCI pose a
challenge to the interventionalist due to patient's comorbidities which
drives worse outcome. Indeed, HRPCI often have severely calcified
complex lesions and multi-vessel coronary artery disease, low creati-
nine clearance, and severe peripheral arterial disease.12 The rationale
for PVAD for HRPCI is for left ventricular (LV) support during periods
of transient hypotension during long coronary balloon inflations and
maintaining coronary perfusion throughout the procedure.13,14
Although guidelines have recommended the use of MCS devices
during HRPCI as a class IIb indication,2 experts have called for further
studies to guide the use of these devices.13
Multiple studies have been conducted to explore the efficacy
of hemodynamic support using IABP during HRPCI with inconsis-
tent results. Reports are mixed in the literature with some
reporting favorable outcomes using IABP during PCI without sig-
nificant difference in mortality.14–16 Other studies have shown no
difference in the outcomes or even a potential harm in IABP use
in high-risk PCI.17–19 Available data from the PROTECT II trial,
which explored the outcome of HRPCI in patients using the
Impella 2.5 as the PVAD compared with IABP demonstrating no
difference in the 30-day major adverse events between both
studied groups.8 However, there was a trend for better outcomes
in the Impella 2.5 group at 90 days and significant improvement
in the per-protocol group.8
Although the PROTECT II trial showed no significant difference in
in-hospital mortality between the Impella 2.5 and the IABP group,8
our study demonstrates that PVAD use was associated with a 36%
statistically significant decreased in-hospital mortality compared with
the IABP after adjusting for potential cofounders. Furthermore, even
after applying propensity score matching, in-hospital mortality was
lower in the PVAD group.
This study has several limitations. NIS is a large, nationally
representative database that has been validated multiple times
for accuracy. Nevertheless, as with all studies that use routinely
collected electronic healthcare data, there are several limitations
to our study. Given the retrospective design, the possibility of
unmeasured confounders is present due to lack of randomization.
Given the high number of outcomes, we adjusted for all potential
covariates available in the database and used propensity score
matching as a sensitivity analysis to correct for differences in
baseline characteristics between groups. ICD-9-CM codes identi-
fied patients who underwent PCI did not account for coronary
artery lesion location or complexity, which could have con-
founded the outcome analysis. Furthermore, frailty is not cap-
tured in the NIS dataset and may confound our analysis through
selection bias, as frail patients are more likely to receive IABP
rather than PVAD, and frailty associated with worse PCI out-
comes which may confound interpretation of data. Further, given
the nature of this database, we were not able to obtain informa-
tion regarding whether successful re-vascularization post-PCI was
achieved or not. In addition, data regarding the conditions the
procedures were performed under, such as the amount of con-
trast used, were not available. Furthermore, acuity of the device
was obtainable using the NIS database which may have con-
founded the mortality and vascular complications outcome of this
study. We did not have information around hemodynamic param-
eters during the course of the procedure, vasopressor use or
hemodynamic compromise which may provide additional informa-
tion around efficacy. Finally, outcome analysis was limited to in-
hospital outcomes as long-term outcomes and complications after
discharge were not recorded.
TABLE 3 (Continued)
Variable
PVAD
group
IABP
group p value
Paralysis (%) 1.9 1.2 .174
Psychosis (%) 1.1 1.2 .848
Renal failure (%) 29.3 23.5 .006
PVD (%) 22.8 20.9 .344
Pulmonary circulation
disorders (%)
0.5 0.5 .947
Peptic ulcer disease
excluding bleeding (%)
0.0 0.0 NA
Valvular disease (%) 0.6 0.7 .906
Weight loss 2.1 2.6 .491
Note: Values are expressed as mean ± SD for continuous variables or
percentages for categorical variables.
Abbreviations: CABG, coronary artery bypass grafting; CAD, coronary
artery disease; IABP, intra-aortic balloon pump; PCI, percutaneous
coronary intervention; PVAD, percutaneous ventricular assist device; TIA,
transient ischemic attack.
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5 | CONCLUSION
The utilization rate of PVAD has been increasing over the course of
recent years in patients undergoing PCI compared to IABP. Based on
this NIS sample analysis, patients who received PVAD had lower in-
hospital mortality and better resource utilization compared with
patients who received IABP. This real-world data analysis sheds much
light into the improved acute outcomes of patients when a PVAD is
utilized.
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